Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interleukin-1 receptor antagonist as therapy for inflammatory disorders
Autore:
Freeman, BD; Buchman, TG;
Indirizzi:
Washington Univ, Sch Med, Trauma & Surg Crit Care, Sect Burn,Dept Surg, StLouis, MO 63110 USA Washington Univ St Louis MO USA 63110 rn,Dept Surg, StLouis, MO 63110 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 2, volume: 1, anno: 2001,
pagine: 301 - 308
SICI:
1471-2598(200103)1:2<301:IRAATF>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; SEPTIC SHOCK; ANTIINFLAMMATORY THERAPIES; DOUBLE-BLIND; TNF-ALPHA; SEPSIS; METHOTREXATE; ENDOTOXEMIA; MULTICENTER;
Keywords:
IL-1; IL-1 receptor antagonist; rheumatoid arthritis; sepsis; septic shock;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Freeman, BD Washington Univ, Sch Med, Trauma & Surg Crit Care, Sect Burn,Dept Surg, 660 S Euclid Ave,Box 8109, St Louis, MO 63110 USA Washington Univ660 S Euclid Ave,Box 8109 St Louis MO USA 63110
Citazione:
B.D. Freeman e T.G. Buchman, "Interleukin-1 receptor antagonist as therapy for inflammatory disorders", EXPERT OP B, 1(2), 2001, pp. 301-308

Abstract

IL-1 is a pivotal mediator of the immune response and has been implicated in inflammatory and infectious diseases. As a consequence, the administration of IL-1 receptor antagonist (IL-1ra), a recombinantly synthesised endogenous inhibitor of IL-1, has appeal as a therapeutic strategy in these conditions. To date, the largest clinical experiences with IL-1ra have been in the setting of sepsis and rheumatoid arthritis (RA). Like other anti-inflammatory agents that target a specific mediator, IL-1ra was found to lack efficacy when given in conjunction with standard therapy in patients with sepsis and septic shock. In contrast, recent studies enrolling patients with RA suggest that IL-1ra significantly ameliorates disease activity and retards joint destruction. Whether the respective lack of efficacy and success of IL-1ra in these two diseases is a result of differences in the pathologic processes involved, or reflects the nature in which the clinical studies wereconducted, is unclear. Further, the effectiveness of IL-1ra compared to other anticytokine and conventional treatments in RA remains to be clarified. Nonetheless, the recent finding that IL-1ra has the ability to favourably influence a chronic inflammatory disease supports the hypothesis that inhibition of a single mediator of the immune response may have clinical impact.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:11:47